ANTIMICROBIAL ACTIVITY AND CLINICAL EFFICACY OF SULBACTAM·AMPICILLIN IN URINARY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement8; pp. 395 - 406
• Main Authors: YAMAHA, MASAYOSHI, ISHIHARA, SATOSHI, HAYASHI, HIDEJI, SHINODA, IKUO, KATOH, HARU, SAITOH, AKIHIRO, TAKEUCHI, TOSHIMI, KANEMATSU, MINORU, BAN, YOSHIHITO, KOMEDA, HISAO, SHIMIZU, YASUO, KAWADA, YUKIMICHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• Subjects: sulbactam·ampicillin
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement8_395

We studied the antimicrobial activity against urinary bacteria and clinical efficacy in urinary tract infections of sulbactam·ampicillin (SBT·ABPC), a new combination drug. This drug consists of sulbactam (SBT), a β-lactamase inhibitor, and ampicillin (ABPC) in a 1:2 ratio. The in vitro activity of SBT·ABPC against Gram-positive bacteria was nearly the same as that of ABPC. SBT·ABPC, however, was more active against Gram-negative bacteria than was ABPC. One patient with acute uncomplicated pyelonephritis and 22 with complicated urinary tract infection were given 1.5g of SBT·ABPC twice a day for 5 days by intravenous route. Clinical efficacy in the patient with acute pyelonephritis was evaluated as excellent. In 17 of the 22 patients with complicated urinary tract infection, it was evaluated by the criteria of the Japanese UTI Committee; excellent and moderate responses were obtained in 82%. Of 21 strains isolated from patients with complicated urinary tract infections, 19 (90%), including 6 high β-lactamase producers, were eradicated after treatment. Clinical adverese reactions were evaluated in 23 patients. Skin rash was observed in 2, but spontaneously resolved after treatment. From the results obtained in this study, SBT·ABPC was considered to be effective in the treatment of urinary tract infections, especially those due to β-lactamase-producing organisms.